SEROQUEL XR� Improved Anxiety Symptoms By Day 4 In Generalised Anxiety Disorder - New Study Results Presented Today

�AstraZeneca announced new SEROQUEL XR� (protracted release quetiapine fumarate) clinical study information in patients with Generalised Anxiety Disorder (GAD), presented at the 21st European College of Neuropsychopharmacology (ECNP) Congress in Barcelona. In this study, extended handout quetiapine fumarate significantly improved symptoms of anxiety at Week 8 compared with placebo and this was observed as early as day 4. The active comparator branch, escitalopram 10mg/day, was as well effective at improving symptoms of GAD at week 8 compared with placebo although improvement was not observed at day 4.



During their lifetimes, it is estimated between 2.7% and 5.4% of people in Europe will suffer from GAD.1 Characteristic symptoms include chronic anxiety, enlarged worry and tension - it is often attended by depression or other anxiety disorders2,3 - and it has a substantial negative impact on Health-Related Quality of Life (HRQoL), productiveness at shape (including absenteeism) and healthcare costs1.



Antidepressants (SSRIs (selective-serotonin reuptake inhibitors) and SNRIs (serotonin and norepinephrine reuptake inhibitors)) are standard treatments that ar generally efficacious but or so 30 per centum of patients treated with SSRIs or SNRIs testament have an inadequate response4. Additionally, they may have got a comparatively slow attack of action, sometimes requiring combination with a myopic course of benzodiazepines (BZDs) to accomplish initial symptom control - however, BZDs may have the potential for dependence and detachment symptoms5.



The data presented today in Barcelona ar the results of Study 10 - conducted across 64 centres in the U.S. and part of the clinical development program for extended release quetiapine fumarate for the treatment of GAD6. A add together of 854 patients aged 18-65 with a DSM-IV3 diagnosis of GAD were randomized to receive either extended vent quetiapine fumarate 150mg/day (n=219), 300mg/day (n=207), escitalopram 10mg/day (n=213) or placebo (n=215). At workweek 8, prolonged release quetiapine fumarate 150mg/day, 300mg/day and escitalopram 10mg/day, significantly decreased mean Hamilton Anxiety Rating Scale (HAM-A) total stacks from randomization compared with placebo (13.9 [p

Both extended tone ending quetiapine fumarate and escitalopram were generally well tolerated. Among lengthened release quetiapine fumarate treated patients, untoward events with incidence greater than 10% and double that of placebo were dry mouth, somnolence, drugging and constipation; among escitalopram-treated patients they were sedation and sickness.



The incidence of AEs associated with EPS among patients treated with extended release quetiapine fumarate 150mg/day, 300mg/day, escitalopram 10mg/day or placebo were 4.2%, 6.0%, 6.8% and 5.7% respectively; the incidence of AEs associated with sexual dysfunction were were 4.1%, 3.9%, 8.1% and 3.7% severally. The proportions of patients who experienced a clinically important budge in fast blood glucose (from normal to >126mg/dL) were 3.7%, 1.6%, 1.1% and 3.2% in the quetiapine fumarate 150mg/day, 300mg/day, escitalopram 10mg/day or placebo groups, severally; the proportions of patients experiencing >7% increase in weight were 3.8%, 3.9%, 0.5% and 0.9% respectively6.

About Generalized Anxiety Disorder (GAD)



GAD is characterized by chronic anxiety, magnified worry, and tension, even when thither is little or zippo to harass it. People with GAD anticipate disaster and are overly interested about health issues, money, family problems, or difficulties at work.2,3



People with GAD can't seem to get rid of their concerns, even though they usually realize that their anxiety is more intense than the place warrants. They can't relax, startle well, and have got difficulty concentrating. Often they have hassle falling asleep or staying asleep. Physical symptoms that often accompany the anxiety include fatigue, headaches, musculus tension, muscle aches, difficulty swallowing, quivering, twitching, excitability, sweating, nausea, lightheadedness, having to go to the bathroom oft, feeling out of breath, and hot flushes. GAD is diagnosed when somebody excessively worries about a number of everyday problems for at least 6 months2,3.

About SEROQUEL and SEROQUEL XR



In May 2008, SEROQUEL XR� (extended release quetiapine fumarate) became the first ever so antipsychotic to complete a clinical development programme and be filed with the FDA in the U.S. for commendation in the treatment of GAD7 - today it is not approved in any country for the treatment of GAD but remains under review with the FDA. SEROQUEL XR� is sanctioned in the US and 28 further countries for the treatment of schizophrenic disorder in grownup patients and for maintenance treatment of schizophrenia in adult patients. It was launched in the US in 2007 and earlier this year AstraZeneca announced the submission of regulatory applications in both the US and European Union for SEROQUEL XR in the treatment of frenzied episodes associated with bipolar disorder, and the handling of depressive episodes associated with bipolar disorder. An sNDA for SEROQUEL XR seeking commendation for the treatment of Major Depressive Disorder in the US was as well announced in February. SEROQUEL XR is not approved for these indications at this clock time and the applications remain under review by the regulatory authorities.



Launched in 1997, it is estimated that SEROQUEL has been prescribed to more than 22 million patients worldwide*. It is approved in 88 countries for the treatment of schizophrenia, in 79 countries for the treatment of bipolar manic disorder, and in 11 countries including the US for the discourse of bipolar depression. It was too recently sanctioned by the FDA in the USA for the for the maintenance treatment of patients with bipolar I upset, as adjunct to atomic number 3 or valproate - a similar submission has been made in Europe.



* Based on assumptions: (1) estimated turn of prescriptions per patient based upon IMS APLD data; and (2) IMS Prescription data for SEROQUEL covering 13 major markets in which this information is uncommitted since the time of launch.

About AstraZeneca


AstraZeneca is a major international healthcare stage business engaged in research, development, manufacturing and marketing of prescription pharmaceuticals and provider for health care services. AstraZeneca is one of the world's ahead pharmaceutical companies with health care sales of US $29.55 1000000000000 and is a leader in gI, cardiovascular, neuroscience, respiratory, oncology and infection product gross sales. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as substantially as the FTSE4Good Index.

http://www.astrazeneca.com

References




1 Wyrwich KW et al. A review of the humanistic and economic outcomes in European patients diagnosed with generalized anxiety disorder. Presented at the 161st Annual Meeting of the American Psychiatric Association, 2008. NR3-065.


2 National Institute of Mental Health: Anxiety Disorders. NIH Publication No. 06-3879. Available here. Accessed 5 August, 2008.


3 Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000:472-475.


4 Bezerra de Menezes G, Fontenelle LF, Mulolo S et al. Treatment-resistant anxiety disorders: social phobic neurosis, generalized anxiety disorder and panic disorderliness. The Brazilian Journal of Psychiatry. 2007; 29(Supplement II):S55-60.


5 Nutt D, Argyropoulos S, Hood S et al. Generalized anxiety disorder: a comorbid disease. European Neuropsychopharmacology (2006) 16, S109-S118


6 Merideth C, Cutler LC196% Neijber A et al. Efficacy and tolerability of extended release quetiapine fumarate (Quetiapine XR) monotherapy in the treatment of GAD. twenty-first ECNP Congress, 2008.


7 Press release: AstraZeneca Submits sNDA for Seroquel XR� for the Treatment of Generalised Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines. 8 May 2008. See: hypertext transfer protocol://www.astrazeneca.com/pressrelease/5392.aspx. Accessed 5 August, 2008.

http://www.astrazeneca.com


View drug information on Seroquel.



More info

• Suit helps the paralysed walk
• Monkeys too experience joy of giving
• Mouth turns virtual PC for disabled
• Noodle ’staves off hunger pangs’
• Mom’s Infection Tied to Preemie Births

Mp3 music: Andy Narell

Artist: Andy Narell: mp3 download    Genre(s):  Jazz New Age     Andy Narell's discography:      The Passage    Year: 2004    Tracks: 7      Live in South Africa    Year: 2001    Tracks: 12      The Long Time Band    Year: 1995    Tracks: 9 Andy Narell introduced the steel drums to jazz as a solo tool, playing not only Caribbean and Latin melodies only R&B, funk, and some straight-ahead jazz. After graduating from the University of California, Berkeley, in 1973, he founded the Hip Pocket mark (which became associated with Windham Hill) and has recorded on a regular base both as a leader and as a sideman ever since. In 1995, Andy Narell became a co-leader of the Caribbean Jazz Project along with Paquito d'Rivera and Dave Samuals, a perfect mercantile ecesis for his virtuosic and colored playing. Since that time, Narell has released a handful of recordings including, among others, Live in South Africa in 2001, Passage in 2004, and Tatoom in 2007.

�90210� Trailer: Brenda! Kelly! Some Other People!

Study Shows Epidural Anaesthesia Is Safe But Only Slightly Improves Survival

�A sketch of quarter of a million patients has shows that epidural anaesthesia anaesthesia / analgesia* (EA) is safe for patients undergoing average to speculative surgery other than cardiac surgery. However people given EA possess only a very slightly increased selection compared with those world Health Organization do not. These ar the conclusions of authors of an Article promulgated early Online and in an forthcoming edition of The Lancet.


EA offers better postoperative pain in the neck relief than intravenous opioid drugs, and also reduces the surgical stress response, which has theoretical benefits for cardiovascular, respiratory, gastrointestinal, and metabolic function. But until now one authoritative question has remained unanswered: do these benefits of EA translate into improved survival for the patients who receive it? Dr Duminda Wijeysundera, from Ontario's Institute for Clinical Evaluative Sciences, and Department of Anaesthesia, Toronto General Hospital and University of Toronto, Canada, and colleagues did a retrospective study of 259 037 Ontario patients to enquire.


The patients in the study were all of age 40 years or over, and had had selected elective intermediate to risky non-cardiac surgery between 1994 and 2004. A total of 56 556 (22%) of these patients standard EA, and the procedure was associated with a small step-down in 30-day mortality (1�7%) compared with patients wHO had non had EA (2�0%). Put another way, 477 patients had to have had EA to avert one death.


The authors conclude: "Epidural anaesthesia was associated with a small improvement in 30-day survival, just this core should be interpreted conservatively. The estimate had borderline significance, despite a large sample size of it. Its absolute magnitude was also modest, corresponding to a number needed to treat of 477. Our study, consequently, does not provide compelling evidence that epidural anaesthesia improves postoperative survival. Nonetheless, our results support the safety of perioperative epidural anesthesia anaesthesia when used for indications other than improving survival - for lesson, improving postoperative pain relief or preventing postoperative lung complications."


In an incidental Comment, Dr Michael Barrington and Dr David Scott, Department of Anaesthesia, St Vincent's Hospital, Melbourne, VIC, Australia, say: "Wijeysundera and colleagues point out that our focus should be on the proven benefits of epidural anesthesia analgesia. The most durable and understandably defined benefit of epidural anaesthesia analgesia is improved analgesia. Provision of effective analgesia is our core job: it has substantial physiological and psychological benefits, and is regarded as a fundamental human right. Pain after major surgery canful be spartan, and we think that in many cases pain relief unequaled is an unambiguous clinical indication for postoperative epidural anesthesia analgesia."

"Epidural anaesthesia and survival after intermediate-to-high risk of exposure non-cardiac surgery: a population-based cohort study"

Duminda N Wijeysundera, W Scott Beattie, Peter C Austin, Janet E Hux, Andreas Laupacis
The Lancet - Published OnlineAugust 11, 2008DOI:10.1016/S0140-6736(08)61121-6


COMMENT
"Do we need to justify epidural analgesia beyond pain relief?"
The Lancet - Published OnlineAugust 11, 2008DOI:10.1016/S0140-6736(08)61122-8

http://www.thelancet.com


More info

• Immigrant kids exercise even less than U.S.-born
• Legal bid to release list of Quebec heart patients with questionable valves rejected
• Food ads target kids, FTC reports
• Weather alerts boost lung health
• Exercise video games get kids off the couch

Beatles Recording Worth Its Weight in Pounds

More than 30 years later, the Beatles' records are smooth golden.

A latterly unearthed reel-to-reel tape of what is believed to be a Fab Four recording session from 1964 was auctioned online Tuesday for 9,300 pounds, or, $23,446 (including tax and handling fees), according to Cameo Auctioneers in the Berkshire

Stud

   
Artist: Stud

   Genre(s): 
Industrial
   Breakbeat
   

---

Discography:


   
 Greetings, Fatherland

   Year: 2007   
Tracks: 10


   
 I Saw The Future

   Year: 2006   
Tracks: 8

---

 

Kiyoshi Yoshida

   
Artist: Kiyoshi Yoshida

   Genre(s): 
New Age
   

---

Discography:


   
 Long Way To Japan

   Year: 2001   
Tracks: 13

---

 





Alec Empire

Sentenced

   
Artist: Sentenced

   Genre(s): 
Metal: Gothic
   Metal
   Rock
   Metal: Death,Black
   

---

Discography:


   
 The Funeral Album

   Year: 2005   
Tracks: 13


   
 Ever-Frost

   Year: 2005   
Tracks: 2


   
 The Cold White Light

   Year: 2002   
Tracks: 11


   
 No One There

   Year: 2002   
Tracks: 2


   
 Cold White Light

   Year: 2002   
Tracks: 11


   
 Live In Paris (La Loco)

   Year: 2000   
Tracks: 11


   
 Crimson

   Year: 2000   
Tracks: 11


   
 Killing Me Killing You

   Year: 1999   
Tracks: 2


   
 Frozen

   Year: 1998   
Tracks: 12


   
 Story - A Recollection (Story - Greatest Kills) (Best Of, Compilation)

   Year: 1997   
Tracks: 13


   
 Greatest Kills

   Year: 1997   
Tracks: 15


   
 Down

   Year: 1996   
Tracks: 11


   
 Love and Death

   Year: 1995   
Tracks: 5


   
 Amok

   Year: 1995   
Tracks: 9


   
 The Trooper

   Year: 1993   
Tracks: 4


   
 North From Here

   Year: 1993   
Tracks: 8


   
 Shadows Of The Past

   Year: 1991   
Tracks: 12


   
 Live Tracks

   Year:    
Tracks: 2

---

The Finnish heavy metal dance band Sentenced released its debut record album, Shadows of the Past, in the early '90s on a little French judge; dissatisfied with their moderately commonplace black-metal good, they hired bassist/vocalist Taneli Jarva to allow more than originality for 1992's Second Earl of Guilford From Here. The criminal record was more than melodic and technically competent and got the band noticed in Sweden; it was followed in 1993 by a four-song EP, The Trooper, the title tune a cover of Iron Maiden's classic. This marked the beginning of a shift toward an even more musical, British metal-influenced style, fleshed out on 1995's Amok and the extra EP Erotic love and Death. Jarva left the band at this point, going away guitarist Miika Tenkula and raw vocalist Ville Laihiala as the musical focus of Sentenced. 1997's Down was the outset exertion by this revamped lineup; it was followed in 1998 by Chronicle: A Recollection, a best-of compilation. The group returned in early 2000 with Crimson and once more in 2002 with The Cold White Light.